TY  - JOUR
A1  - Schlagenhauf, Ulrich
A1  - Jakob, Lena
A1  - Eigenthaler, Martin
A1  - Segerer, Sabine
A1  - Jockel-Schneider, Yvonne
A1  - Rehn, Monika
T1  - Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT
JF  - Journal of Clinical Periodontology
N2  - Aim: 
This randomized controlled trial assessed the impact of Lactobacillus reuteri on pregnancy gingivitis in healthy women. 

Materials and Methods: 
Forty-five healthy women (24 test/21 placebo) with pregnancy gingivitis in the third trimester of pregnancy were enrolled. At baseline Gingival Index (GI) and Plaque Index (PlI) were assessed at the Ramfjord teeth and venous blood taken for TNF-alpha analysis. Subsequently participants were randomly provided with lozenges to be consumed 2 9 daily until birth (approx. 7 weeks) containing >= 10(8) CFU L. reuteri ATCC PTA 5289 and >= 10(8) CFU L. reuteri DSM 17938 (test) or being devoid of L. reuteri (placebo). Within 2 days after birth recording of GI, PlI and blood sampling were repeated. 

Results: 
At baseline, mean GI and mean PlI did not differ significantly between both groups. In the test group mean TNF-alpha serum level was significantly (p < 0.02) lower than in the placebo group. At reevaluation, mean GI and mean PlI of the test group were both significantly (p < 0.0001) lower than in the placebo group. Mean TNF-alpha serum level did no longer differ significantly between the groups. 

Conclusions: 
The consumption of L. reuteri lozenges may be a useful adjunct in the control of pregnancy gingivitis.
KW  - chronic periodontitis
KW  - probiotic lozenges
KW  - subgingival
KW  - bacteria
KW  - postpartum
KW  - microbiota
KW  - disease
KW  - L. reuteri
KW  - plaque
KW  - pregnancy
KW  - pregnancy gingivitis
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-186783
VL  - 43
IS  - 11
ER  - 
TY  - JOUR
A1  - Harks, Inga
A1  - Jockel-Schneider, Yvonne
A1  - Schlagenhauf, Ulrich
A1  - May, Theodor W.
A1  - Gravemeier, Martina
A1  - Prior, Karola
A1  - Petersilka, Gregor
A1  - Ehmke, Gregor
T1  - Impact of the Daily Use of a Microcrystal Hydroxyapatite Dentifrice on De Novo Plaque Formation and Clinical/Microbiological Parameters of Periodontal Health. A Randomized Trial
JF  - PLoS ONE
N2  - Aim
This 12-week prospective, randomized, double-blind, two-center trial evaluated the impact of a microcrystalline zinc hydroxyapatite (mHA) dentifrice on plaque formation rate (PFR) in chronic periodontitis patients. We hypothesized that mHA precipitates cause delayed plaque development when compared to a fluoridated control (AmF/SnF\(_{2}\)), and therefore would improve periodontal health.

Material & Methods
At baseline and after 4 and 12 weeks, PFR and other clinical and microbiological parameters were recorded. Seventy periodontitis patients received a mHA or AmF/SnF\(_{2}\) dentifrice as daily oral care without hygiene instructions. Four weeks after baseline, participants received full mouth debridement and continued using the dentifrices for another 8 weeks.

Results
Primary outcome PFR did not change statistically significantly from baseline to weeks 4 and 12, neither in mHA (n = 33; 51.7±17.2% vs. 48.5±16.65% vs. 48.4±19.9%) nor in AmF/SnF2-group (n = 34; 52.3±17.5% vs. 52.5±21.3% vs. 46.1±21.8%). Secondary clinical parameters such as plaque control record, gingival index, bleeding on probing, and pocket probing depth improved, but between-group differences were not statistically significant. Microbiological analyses showed similar slight decreases in colony-forming units in both groups.

Conclusion
In patients with mild-to-moderate periodontitis, periodontal therapy and use of a mHA-or AmF/SnF\(_{2}\) dentifrice without instructions induced comparable improvements in periodontal health but did not significantly reduce the PFR.
KW  - microcrystalline zinc hydroxyapatiteimpact
KW  - plaque formation
KW  - periodontal health
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-166853
VL  - 11
IS  - 7
ER  -